ConCallIQ
Go Pro

Sunpharma FY25 Annual Earnings Summary

4 quarters covered · ₹52,041 Cr revenue · ₹10,929 Cr PAT · 29.0% average EBITDA margin.

Total annual revenue: ₹52,041 Cr
Annual PAT: ₹10,929 Cr
Average margin: 29.0%
Promise delivery: 0%

Quarter-by-quarter progression

QuarterRevenuePATMarginSentiment
Q1 FY25₹12,525 Cr₹2,836 Cr28.5%bullish
Q2 FY25₹13,264 Cr₹3,040 Cr29.6%bullish
Q3 FY25₹13,437 Cr₹2,903 Cr29.3%bullish
Q4 FY25₹12,816 Cr₹2,150 Cr28.7%neutral

Management promises made during the year

R&D spend to be 8-10% of sales in FY25

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q1 FY25
missed
Deuruxolitinib launch post-PDUFA date (July 2024)

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q1 FY25
missed
R&D spend to step up to 8-10% of sales for FY25

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q2 FY25
missed
Leqselvi launch pending court decision on preliminary injunction

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q2 FY25
missed
R&D spend to be 7-8% of sales for FY25

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q3 FY25
missed
FY25 R&D spend to be less than 7% of sales

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q4 FY25
missed
Specialty sales growth to normalize after Q3 inventory build

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q4 FY25
missed

Risks flagged during the year

Q1 FY25 · high

Incyte filed a preliminary injunction motion to block Leqselvi launch; outcome uncertain and could delay revenue contribution.

Q2 FY25 · high

The Leqselvi launch depends on a favorable court ruling on the '335 patent; an unfavorable outcome could delay launch until patent expiry in Dec 2026.

Q3 FY25 · high

Halol facility remains under FDA scrutiny; reinspection has been invited but not scheduled, delaying new product approvals.

Q3 FY25 · high

If the patent litigation outcome is unfavorable, Leqselvi launch could be delayed until December 2026, impacting specialty growth.

Q4 FY25 · high

Lack of clarity on MFN and tariff policies could impact US specialty pricing and access.

Q4 FY25 · high

Leqselvi launch may be at risk due to ongoing patent litigation; potential damages if lost.

Q1 FY25 · medium

Management plans to request FDA re-audit once ready, but no specific timeline provided; pending approvals may impact U.S. generic pipeline.

Q1 FY25 · medium

U.S. generic sales were flat sequentially; Revlimid contribution was not large this quarter, and sustainability is uncertain.

Q2 FY25 · medium

Management acknowledged that further delays in clinical trials could keep R&D spend below the revised 7-8% guidance.

Q2 FY25 · medium

Other expenses rose significantly due to higher selling and distribution costs in US and EM, which could pressure margins if not offset by revenue growth.

Q2 FY25 · medium

Price cuts in Japan are expected to continue pressuring ROW revenues for the next few quarters, as mentioned by management.

Q3 FY25 · medium

Potential US tariff changes and new administration policies could impact Sun Pharma's US generics and specialty business.

What changed through the year

G

Q1 FY25 · R&D spend to step up to 8-10% of sales for FY25

Management expects R&D investment to increase in subsequent quarters, with full-year guidance of 8-10% of sales.

G

Q1 FY25 · Effective tax rate to increase on full-year basis

Tax rate expected to rise due to expiry of certain exemptions; should be viewed on an annualized basis.

G

Q1 FY25 · Leqselvi launch pending court decision on preliminary injunction

Launch timing of Leqselvi will be governed by court ruling on Incyte's motion; company opposes and seeks early outcome.

G

Q2 FY25 · R&D spend to be 7-8% of sales for FY25

R&D spend for FY25 is expected to be in the range of 7-8% of sales, down from earlier guidance of 8-10%, due to delays in clinical studies.

G

Q2 FY25 · Leqselvi launch readiness within weeks of favorable judgment

Management stated they would be ready to launch Leqselvi within a couple of weeks post a favorable court ruling on the patent litigation.

G

Q2 FY25 · Ilumya PsA Phase III data expected H2 CY2025

Phase III data for Ilumya in psoriatic arthritis is expected in the second half of calendar year 2025, with launch shortly after approval.

G

Q3 FY25 · FY25 R&D spend to be less than 7% of sales

Due to delays in clinical trial initiation, R&D expenditure for FY25 is expected to be below the earlier guidance of 7% of sales.

G

Q3 FY25 · Leqselvi launch timeline dependent on litigation outcome

Oral arguments for Leqselvi patent litigation expected in April 2025; if favorable, launch could occur before patent expiry in December 2026.

G

Q3 FY25 · Specialty sales growth to normalize after Q3 inventory build

Q3 specialty sales benefited from inventory build at a partner; next quarter sales are expected to be lower excluding milestones.

G

Q4 FY25 · FY26 revenue growth: mid-to-high single digit

Management expects consolidated top-line growth of mid-to-high single digits for FY2026.

G

Q4 FY25 · Additional $100M investment in specialty launches

Approximately $100 million additional spend in FY26 for commercialization of new specialty products.

G

Q4 FY25 · R&D spend guidance: 6%-8% of sales

FY2026 R&D spend expected to be 6%-8% of sales.

G

Q4 FY25 · Leqselvi launch in Q2 FY26

Leqselvi to be launched in the US in the second quarter of FY2026.